நுரையீரல் & சுவாச மருத்துவம்

Treatment Associated Interstitial Pulmonary Toxicity of Temozolomide Plus Bevacizumab for Locally Advanced Solitary Fibrous Tumor

Abstract

Heissner K, Horger M, Spengler W, Steger V, Kanz L, Biro D and Kopp HG

Solitary Fibrous Tumors (SFT), previously termed haemangiopericytoma, are rare soft tissue sarcomas (STS). They usually grow slowly and show indolent behaviour in terms of malignancy. Surgery in localized disease is the only curative approach. While metastatic disease occurs rarely, locally advanced SFT often require systemic treatment. Systemic treatment for inoperable SFT is not standardized, and chemotherapy displays only modest activity. Temozolomide plus bevacizumab is a relatively active treatment option. Its advantages are prolonged tumor stabilisation combined with an overall low toxicity profile. We report the first case of treatment related interstitial pulmonary toxicity caused by temozolomide in combination with bevacizumab during treatment of SFT.